FDA still concerned by crystals in UCB's Neupro
This article was originally published in Scrip
Executive Summary
The US FDA has issued a complete response letter to UCB, requesting that the company reformulate its restless leg syndrome (RLS) and Parkinson's drug Neupro (rotigotine). Analysts say this could cause a two year delay before the company is able to relaunch the therapy.